|
|
Volumn 8, Issue 9, 2012, Pages 1360-1363
|
|
Cancer vaccines and immunotherapeutics: Challenges for pricing, reimbursement and market access
|
|
Author keywords
Cancer; Cost effectiveness; Immunotherapeutics; Reimbursement; Vaccines
|
|
Indexed keywords
ABIRATERONE;
ABIRATERONE ACETATE;
CABAZITAXEL;
ENZALUTAMIDE;
IPILIMUMAB;
RADIUM CHLORIDE RA 223;
SIPULEUCEL T;
VEMURAFENIB;
WART VIRUS VACCINE;
CANCER IMMUNIZATION;
CANCER IMMUNOTHERAPY;
CASTRATION RESISTANT PROSTATE CANCER;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG COST;
DRUG MARKETING;
ECONOMIC EVALUATION;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE COST;
HEALTH PROGRAM;
HUMAN;
KIDNEY CANCER;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
METASTATIC MELANOMA;
NOTE;
PAPILLOMAVIRUS INFECTION;
PROSTATE CANCER;
QUALITY ADJUSTED LIFE YEAR;
REIMBURSEMENT;
SURVIVAL TIME;
VACCINATION;
CANCER VACCINES;
FEMALE;
HUMANS;
IMMUNOTHERAPY;
MALE;
|
|
EID: 84866989474
PISSN: None
EISSN: 2164554X
Source Type: Journal
DOI: 10.4161/hv.21921 Document Type: Note |
|
Times cited : (15)
|
|
References (16)
|
